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Accurate detection of sentinel lymph node status
in the axilla of breast cancer patients is essential to
avoid unnecessary axillary lymph node dissection
(ALND).1–3 Even for breast cancer patients with
clinically negative sentinel lymph nodes (SLNs),
the standard of care involves an integrated team
consisting of breast surgeons, nuclear medicine ex-
perts and pathologists. Validation of the existence
of SLNs is necessary because it provides a 95%
interval of confidence in assessing the pathologic
status of axilla. The false negative result (FNR)
should be as low as possible and a less than 5%
FNR is accepted universally.4 Once validation is
achieved, sparing the SLN negative breast cancer
patient from ALND surgery is considered safe.
The incidence of pathologically negative axilla
in Taiwanese breast cancer patients increased from
24% (stage 0, 12%; stage I, 12%) to 46.2% (stage 0,
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15.4%; stage I, 30.8%) after vigorous promotion
of a breast cancer screening program.5 In 1998,
breast surgeons in Taiwan began performing SLN
biopsy validation in an attempt to spare clinically
negative axilla breast cancer patients from ALND.
Two years later, the first SLN workshop was held
on July 3, 2000 at Taichung Veterans General
Hospital with the participation of an SLN biopsy
team from the University of California at San
Francisco.6 Thereafter, many other breast surgeons
from Taiwan have adopted this new approach.
After the SLN symposium in the 4th Asian Breast
Cancer Conference in Taipei in February 2004,7
data were collected nationwide to evaluate the
results of SLN biopsy validation in Taiwanese
breast cancer patients. The first set of collaborative
data were collected from 11 institutions and pre-
sented at the second SLN biopsy workshop in
August 2004 at Tri-Service General Hospital.8 A
second set of collaborative data was accrued from
the original 11 and an additional five hospitals.
This study analyzed the validity of the clinical data
collected in these two periods.
Materials and Methods
Study period and subjects
Data collected in the period January 1999 to July
31, 2004 were compared with data from August
1, 2004 to February 28, 2005. Patients < 80 years
old with pathologically confirmed breast cancer
with cT2 (< 5 cm) tumor, without palpable lym-
phadenopathy at axillary fossa were included.
Data on pathologic staging was not collected, but
a clinically negative axilla was required to validate
whether SLN biopsy could replace conventional
ALND.
Questionnaire
Breast surgeons from 11 hospitals provided data
in both periods, and those from five additional
hospitals only responded in the later period. Data
collected by questionnaire included the kinds of
tracer used, timing and location of tracer injection,
SLN success biopsy rate, average and maximum
number of SLNs harvested, background and cri-
teria of SLN biopsy completion when using iso-
tope as the tracer, intraoperative SLN examination
and its agreement with permanent section rate,
case number of positive cytokeratin staining and
its conversion pathologic diagnosis from nega-
tive to positive. Results obtained for SLNs and
axillary lymph node (ALNs) were compared with
regard to final pathology, FNR and the number
of patients who were spared ALND.
Statistical analysis
Student’s t test was used to compare the difference
in FNR between surgeons who had experience
with more than or less than 100 cases. The differ-
ence between two groups was considered signifi-
cant if p was less than 0.05.
Results
A total of 3308 patients were included in this
study. Of them, 1964 were treated in one of 11
hospitals in the initial period and 1344 were
treated in one of 16 hospitals in the later period.
ALND-sparing surgery was performed on 340 
patients in the initial period and on 350 patients
in the later period.
SLN biopsy methods
Table 1 compares the SLN biopsy methods used
in the two study periods.
Tracer
In the initial period, 45% (5/11) of hospitals used
combined blue dye and isotope as tracer, and in
the later period, 80% (13/16) of the hospitals used
combined tracers. Uncharacteristically, one hospi-
tal preferred to use blue dye alone and two oth-
ers preferred to use isotope alone as the tracer
throughout the two periods. The blue dyes used
as the tracer in the initial period were methylene
blue, patent blue V and charcoal. No hospital
used lymphozurin as the tracer during the entire
study. One hospital used charcoal in the initial
period but discontinued it in the later period
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and instead used combined methylene blue and
isotope. Patent blue V was the most frequently
used blue dye tracer of choice in the later period
(12/14). Filtered sulfur colloids (< 200 nm) were
the primary legend agent used in isotope tracer in
all hospitals except two, which preferred to use
unfiltered (> 1000 nm) sulfur colloids in both pe-
riods. Labeling 1 mCi technetium-99m was used
in all hospitals except one, which used 2 mCi and
unfiltered sulfur colloids as well. When isotope
was used as the tracer, use of the abdomen as the
background increased from 60% (3/5) in the ini-
tial period to 87% (13/15) in the later period. The
remaining hospitals favored 10% radioactivity in
the hottest node in the axilla as the background.
Timing of tracer use and injection site
Blue dye was injected just before incision in all
cases. Isotope was most often injected before the
day of operation in all hospitals. Three hospitals
in the initial period and one in the later period
preferred to inject isotope on the day of operation.
The periareola plus subdermal areas were the most
common injection site in both periods, and three
hospitals also preferred to perform an additional
injection in the peritumor area. Only one hospi-
tal favored injecting in the subdermal area alone.
Background and SLN biopsy completion criteria
Three hospitals in the early and two in the later
period chose the hottest node in the axilla as the
basic background, i.e. they selected 10% radio-
activity in the hottest node as the threshold for
completed SLN resection. The remaining hos-
pitals preferred abdominal radioactivity as the
background. Notably, one hospital in the early
period did not use any specific location as the
background and had no specific criteria for SLN
completion. This hospital chose the abdomen as
background in the later period. One hospital in
the early period used both methods but omitted
the hottest node in the later period. One newly
participating hospital preferred zero radioactivi-
ties at the axilla as the SLN completion criteria.
SLN biopsy results
Table 2 compares the SLN biopsy results in the
two periods.
SLN identification/biopsy success rate
After tracer injection, only 45.5% (5/11) of insti-
tutes in the early period achieved a 95% SLN iden-
tification success rate, whereas five other hospitals
(45.5%) had a lower than 85% or 90% rate and
one hospital had only an 80% success rate for
SLN identification. In the later period, 12 out of
16 hospitals (75%) achieved a 95% success rate
for SLN identification. Of the remaining three
new participating hospitals, two had a success
rate of at least 90% and one had an 85% success
rate for SLN identification. Another one hospital
using large colloid for SLN biopsy clinical trial 
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Table 1. Comparison of lymph node biopsy
methods used in the two study periods
Period Initial* Later*
Tracer
Blue dye 2 1
Isotope 4 2
Combined 5 13
Blue dye
Methylene blue 3 2
Patent blue V 3 12
Charcoal 1 0
Isotope dose
1 mCi 8 14
2 mCi 1 1
Colloid size
< 200 nm 7 13
> 1000 nm 2 2
Time of isotope injection
Day of operation 3 1
Day before operation 3 10
Both 3 4
Background of isotope
Hottest node in axilla (1) 3 2
Abdomen (2) 4 12
0 radioactivity in axilla 0 1
(1) + (2) 1 0
No need 1 0
*The number in both periods represents the number of hospitals
in which the procedure was used.
in the early period still had a 90% SLN biopsy
success rate in the later period. None of the hos-
pitals had a 100% successful identification rate.
Average and maximum number of SLNs harvested
Hospitals using blue dye only harvested one to
two SLNs on average and a maximum of three
SLNs. The percentage of cases with a maximum
number of harvested SLNs of three to four or
more on average increased from 45% in the early
period to 63% in the later period. The percentage
of patients with a maximum number of harvested
SLNs of more than six increased from 82% in the
early period to 88% in the later period. Three
hospitals in the early period and four hospitals
in the later period harvested a maximum of 12 or
more SLNs respectively.
Intraoperative SLN pathologic examination and 
its rate of agreement with permanent section
Two hospitals in the early period and one in the
later period did not conduct any intraoperative
SLN examination. In the early period, five hospi-
tals used frozen section, two used Cyto-print and
two used both methods. In the later period, 11 hos-
pitals used frozen section; of them, five were from
the original group of hospitals, five were from the
new group and one was from a hospital not origi-
nally performing intraoperative examination. One
hospital had a 100% match rate between the re-
sults of frozen section and permanent section in
the early period, but the match rate decreased to
95% in the later period. In the early period, only
two hospitals had a 95% match rate and another
six hospitals had a 90% match rate. In the later pe-
riod, the majority (13/15) of included hospitals
had a 95% match rate, and only two of the newly
included hospitals had a 90% match rate.
Cytokeratin staining
All cytokeratin staining results on the negative
SLNs were obtained from subsequent permanent
sections. Two hospitals in the early period and
10 in the later period used this method. Upstaging
of breast cancer based on cytokeratin staining re-
sults occurred in 10 out of 359 patients in the early
period and 31 out of 912 patients in the later pe-
riod. Of these 41 patients, no cancer metastasis
was found in other non-SLNs after ALND.
False negative rate and sparing of ALND
The FNR in the early period was <7% in eight hos-
pitals and > 7% FNR in three hospitals. Table 3
compares results for the two periods including
the number of SLN biopsy cases, number of pos-
itive SLN versus false negative cases, FNR, and the
number of ALND-sparing cases in the eight hos-
pitals with FNR < 7% in the early period. Two of
these hospitals did not report the number of cases
with SLN biopsy or the FNR, but did report the
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Table 2. Comparison of sentinel lymph node (SLN)
biopsy results in the two study periods
Period Initial* Later*
SLN biopsy success rate (%)
100 0 0
95 5 12
90 4 3
85 1 1
80 1 0
Average/maximal SLN number
1–2/3 3/2 3/2
2–3/6 3/4 4/7
3–4/9 4/2 8/3
> 4/12 1/3 1/4
Intraoperative SLN examination
Not done 2 1
Frozen section 5 11
Cyto-print 2 2
Both 2 2
Match with permanent section (%)
100 1 0
95 2 13
90 6 2
85 0 0
Cytokeratin conversion cases (n)
Not done/not available 6/3 4/2
1–3 1 6
4–6 0 2
7–9 1 2
*The number in both periods represents the number of hospitals
in which the procedure was used.
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number of cases spared ALND in the later period.
Comparison of the FNR in the two periods for
the other six hospitals revealed a decrease of FNR
around 5% in the later period but the number of
patients spared ALND did not increase in pro-
portion with the increased number of SLN biopsy
cases. Table 4 compares the FNR and number of
patients spared ALND in hospitals with FNR >7%
in the initial period, including the five newly par-
ticipating hospitals in the later period. The three
hospitals with FNR > 7% in the initial period had
a decrease in FNR to 0% and did not perform
ALND-sparing surgery in the later period. Of the
five newly participating hospitals in the later 
period, four had FNR < 5%, and one had an FNR
of 37.5%; the surgeon-in-charge in that hospital
performed ALND-sparing surgery on 15 patients.
Analysis of the accumulated case number in
each institute and its relation to the resulting FNR
revealed that breast surgeons with more than 100
cases of experience had significantly lower FNR
than those with a case experience of less than 100
(average FNR 3.8 vs. 8.2, p < 0.01).
Discussion
Blue dye has the advantages of no radiation dam-
age, easy injection during surgery, clear demonstra-
tion of the lymphatic channel near a SLN, short
waiting time for tracer spread, and no need for a
sophisticated detection instrument. However, its
disadvantages include harvest of a small number
of SLNs due to short staining time, difficulty in
Table 3. Comparison of false-negative rate (FNR) and number of patients spared axillary lymph node
dissection (ALND) in hospitals with initial FNR < 7%
SLN cases (n) SLN+/F FNR (%) ALND spared (n)
Initial Later Initial Later Initial Later Initial Later
140 NA 46/0 NA 0 NA 134 41
124 NA 43/0 NA 0 NA 4 32
43 36 30/1 33/1 3.3 3.1 92 17
814 355 286/10 18/0 3.5 0 30 36
111 63 22/1 16/1 4.3 5.8 18 16
219 71 73/5 23/1 6.4 4.2 8 18
165 58 45/3 18/1 6.4 5.8 20 22
251 77 66/5 33/2 7.0 5.7 20 12
SLN = sentinel lymph node; SLN+/F = SLN positive number/false negative number; NA = not available.
Table 4. Comparison of false-negative rate (FNR) and number of patients spared axillary lymph node
dissection (ALND) in hospitals with FNR > 7% in the initial period and newly participating hospitals
SLN cases (n) SLN+/F FNR (%) ALND spared (n)
Initial Later Initial Later Initial Later Initial Later
50 51 7/2 8/0 22 0 6 0
32 42 10/2 5/0 17 0 6 0
15 28 3/1 7/0 33 0 2 0
131 113/2 1.7 10
35 5/3 37.5 15
204 55/2 3.5 36
114 23/1 4.2 19
79 19/1 5.0 76
SLN = sentinel lymph node; SLN+/F = SLN positive number/false negative number.
identifying SLNs due to bleeding during opera-
tion, blue coloration in the breast and urine and
anaphylactic reaction.9 While the lethal compli-
cation in previous studies was usually caused by
lymphozurin, this blue dye is not available in
Taiwan. This explains why anaphylactic reaction
did not occur in this study.
Use of an isotope has the advantages of har-
vest of a large number of SLNs, no interference
from bleeding during SLN identification, and a
small incision wound. However, the procedure
requires a special gamma detector, is limited to
hospitals with nuclear medicine facilities, requires
at least 2 hours of waiting time after injection,
and may expose patients, surgeons and patholo-
gists to harmful radiation.10 The radiation dose
of 1–2 mCi technetium-99 is in the accepted
safety range according to the Medical Internal
Radionuclide Dosimetry Committee of the Society
of Nuclear Medicine in the USA.11 When using
legend colloid, the smaller the molecule, the more
SLNs will be shown and vice versa. Unfiltered col-
loid smaller than 1000 nm is universally accepted
as adequate to identify SLN.12
Both blue dye and isotope can identify SLNs
in the axilla during surgery with rates of 90% 
to 92% respectively. However, previous studies
showed that combined use of these two agents
could provide an extra capability of identifying
SLN during surgery, with an increase of up to 98%
compared to using either agent alone.10,13 In this
study, the number of hospitals that used the
combined tracer method doubled in the later pe-
riod. This is partially reflected by the 95% in-
crease in the SLN biopsy success rate in the later
period. Nevertheless, hospitals, which used only
one tracer, still had a SLN biopsy success rate
> 95%. This is largely attributable to having ac-
quired enough experience to conduct this proce-
dure. However, one hospital that used 2 mCi Tc-99
legend with more than 1000 nm colloid had only
an 85% SLN biopsy success rate. It is possible
that the use of a too large colloid was responsible
for the decreased number of SLNs identified and
harvested. In addition, use of a higher dose of
isotope did not improve the SLN biopsy success
rate in this hospital. The isotope was usually in-
jected on the day before biopsy to allow more
time for surgery on the following day and to im-
prove the SLN biopsy success rate.14 A previous
study found that multiple injections of tracer on
the tumor and nipple-areola complex revealed
more SLNs through different lymphatic drainage
channels.15 In the later period of this study, more
hospitals advocated this approach, which may
partly explain the higher SLN biopsy success rate.
When isotope was used in SLN biopsy, the back-
ground was essential for SLN identification based
on the comparative radioactivity count between
SLN and background.16 A procedure, which re-
quires > 10% radioactivity count in the hottest
node in the axilla, has been outlined in many
studies and was performed at two hospitals in
this study. Such a procedure might pose a risk of
concealing a hot node with cancer metastasis in
the axilla due to missing the hottest node in the
first biopsy step.3 When using the abdomen as
background, every hot node in the axilla, whether
positive or negative for cancer metastasis, will be
found. The only drawback to this approach is
that it requires more biopsy steps and takes more
time to complete in a patient with multiple SLNs. 
In this study, more hospitals (87%) selected the
abdomen as the background in the later period
compared to the early period (56%). A standard
assumption in SLN biopsy is that the more SLNs
harvested, the lower the resulting FNR.17 In this
study, the increased identification success rate
and decreased FNR showed that it was worth-
while to take more time during surgery.
Intraoperative SLN pathologic examination
can provide information regarding cancer metas-
tasis and ALND can be performed immediately
afterwards. In this study, all but two hospitals in
the early period and one in the later period used
such a procedure. Some pathologists were con-
cerned that a frozen section procedure would
consume tissue, which could harbor microscopic
metastatic lesions. As pathologists accumulated
more experience, the diagnostic accuracy rate in-
creased. A previous study reported that the key to
increasing the matching rate was to use multiple
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sections on each SLN instead of the traditional
bi-halved method,18 and this method was intro-
duced in the two SLN workshops in February
2003 and August 2004. A more than 95% increase
in accuracy rate occurred from 22% in the early
period to 87% in the later period. One hospital
had a 100% matching rate in the early period de-
spite experience with less than 20 cases; the rate
decreased to 95% in the later period, after treat-
ment of a total of 50 cases. The Cyto-print method
has the advantage of zero tissue consumption with
results equivalent to frozen section. However, ac-
cording to previous reports, nearly 20% of find-
ings are suspicious and a subsequent permanent
section is required for proof. Besides, an experi-
enced cytologist is needed to use this approach.19
Micrometastatic lesions can also be found by
meticulous intraoperative review of multiple sec-
tions of SLN. Cytokeratin immunohistochemical
staining can highlight micrometastasis, which may
be hidden on hematoxylin and eosin staining in
SLN, resulting in a change in the staging of breast
cancer. Surgeons and pathologists who partici-
pated in this study were highly in favor of this 
examination during the later period. In this study,
the number of cases, which were converted from a
negative SLN result to a positive result increased
as more hospitals performed this examination
routinely.
The SLN biopsy confidence rate for solid can-
cer should be validated based on the results for
FNR; too high a value of FNR is not acceptable.20
It has been well documented that breast cancer
metastasis to axillary lymph node has a 3–5%
skip metastatic rate; positive lymph nodes have
been found in higher level axilla but not in lower
axilla.21 Therefore, a 5% FNR is acceptable in SLN
biopsy of breast cancer patients.4 In the initial
period of this study, eight hospitals had an FNR
< 7%, while in the later period this rate decreased
to < 5%. Notably, seven of these hospitals had
more than 100 cases of accumulated experience
in the initial period. The remaining three hospi-
tals had an initial FNR > 7% and had less than 50
cases of experience in the initial period. The FNR
in these hospitals, however, decreased to 0% in
the later period as with the accumulation of ac-
cumulated over 100 cases of experience. In addi-
tion, ALND-sparing surgery was not performed
in these three hospitals in the later period for the
sake of patient safety. The impact of the two SLN
workshops was apparent and more experience
was required to improve the skill levels for every
breast surgeon. The five newly participating hos-
pitals in the later period had an FNR similar to
that of the original 11 hospitals. Another hospi-
tal with only 35 cases of experience had an FNR
of 37.5% and performed ALND-sparing surgery
on 15 patients. The surgeon responsible for all
case data in that hospital was asked to suspend
future ALND-sparing surgery until his FNR in
SLN biopsy decreased to less than 5%.
Bass et al analyzed the relation between case
experience and FNR and concluded that at least
30 cases were needed to reach a 5% FNR,22 and
that a false-negative event was usually encountered
in the first 30 cases of SLN biopsies. However,
this study found that experience with at least 100
cases resulted in an acceptable FNR and that pa-
tients undergoing ALND-sparing surgery in such
environments will be safe. Recently, the axillary
recurrence rate in ALND-sparing surgery patients
with negative SLN was estimated to be around
0.32% after 2.5 years of follow-up.23 Although
many institutes have reached a safe range with
regard to FNR, breast surgeons in Taiwan are still
reluctant to perform ALND-sparing surgery on
breast cancer patients with negative SLN due to a
lack of nationwide collaborating supporting evi-
dence. Further, current practices are not based on
validation from a large population. Based on the
results of the study of Bass et al22 and the results
of this study, the Taiwan Breast Society developed
compromised guidelines stating that experience
with at least 50 cases of SLN biopsy validation is
needed for a breast surgeon to safely perform
ALND-sparing surgery on breast cancer patients
with negative SLN. This is also in agreement with
the findings of the EORTC Breast Cancer Group.24
Therefore, a nationwide one-arm SLN biopsy
protocol in breast cancer requiring that breast
surgeons have validated experience of at least 50
T.J. Liu
132 J Formos Med Assoc | 2007 • Vol 106 • No 2
Validity of SLNB in Taiwan breast cancer patients
J Formos Med Assoc | 2007 • Vol 106 • No 2 133
SLN biopsies with FNR <5% will be recommended
by the Taiwan Breast Society and the National
Health Research Institute in order to ensure the
best quality of life for breast cancer patients with
negative SLN undergoing ALND-sparing surgery.
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